Phaseline

Companies › The Skin Center Dermatology Group

The Skin Center Dermatology Group: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 4, 1 Phase 2, 1 Phase 1; Infectious disease, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tirbanibulin
Tyrosine-protein kinase SRC inhibitor
SRCPhase 4Warts Hand; Cell Carcinoma; Keratinocyte CarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06791525TirbanibulinPhase 4Warts HandInfectious diseaseDec 2026
NCT06112522TirbanibulinPhase 2Cell CarcinomaOncologyDec 2027
NCT07010692TirbanibulinPhase 1Keratinocyte CarcinomaOncologyMay 2030

Targets

SRC (1)

Companies with the same targets

Nuvectis Pharma Turning Point Therapeutics Almirall

Companies built like this

Cantex Pharmaceuticals Tetraphase Pharmaceuticals Amivas Shanghai Jiatan Pharmatech Laboratorio Farmaceutico SIT srl

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.